Brief: AB Science: Update On Masitinib Phase 3 Study (Ab12003)
31/03/2021 17:20
March 31 (Reuters) - AB SCIENCE SA ABS.PA :
* AB SCIENCE PROVIDES AN UPDATE ON THE EXPECTED TIMELINES
FOR THE
READ-OUT OF ITS MASITINIB PHASE 3 STUDY (AB12003) IN METASTATIC
CASTRATE-RESISTANT PROSTATE CANCER
* FINAL RESULTS OF STUDY AB12003 WILL BE AVAILABLE IN APRIL
2021
Source text for Eikon: ID:nGNE7DpMN9
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease